Improved Cognitive Processing Speed With Ublituximab in Patients With Highly Active Relapsing Multiple Sclerosis By admin / 06/02/2022
Infusion-Related Reactions With Ublituximab in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/02/2022
Reduced Disease Progression With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/02/2022
Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) By admin / 04/05/2022
Disability Improvements with Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations from the Phase 3 ULTIMATE I and II Studies By admin / 04/03/2022
Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) By admin / 04/03/2022
Infusion-Related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses from the Phase 3 ULTIMATE I and II Studies By admin / 04/03/2022
Reduction in T1 Hypointense Lesions with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients with Relapsing Multiple Sclerosis By admin / 02/24/2022
Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
